Novel FLT3 tyrosine kinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 12, Issue 12, 2003, Pages 1951-1962

  Levis, Mark ^a   Small, Donald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; FLT3; Kinase inhibitor; Tyrosine kinase

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AGL 2033; AGL 2043; AMI 10706; CEP 701; D 64406; GTP 14564; IMATINIB; INDOLE DERIVATIVE; K 252A; MIDOSTAURIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINOXALINE DERIVATIVE; RETINOIC ACID; SEMAXANIB; STAUROSPORINE; SU 5614; SUNITINIB; THRX 165724; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; CELL ASSAY; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; IN VITRO STUDY; LABORATORY TEST; NONHUMAN; PROGNOSIS; REVIEW; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0346258290     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.12.1951     Document Type: Review

References (107)

1. BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355-365.
2. ALEXANDER WS, NICOLA NA: Hemopoietic growth factor receptor abnormalities in leukemia. Leuk. Res. (1998) 22:1097-1111.
3. REILLY JT: Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. (2002) 116:744-757.
4. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348:1201-1214.
5. GILLILAND DG, GRIFFIN JD: The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 100:1532-1542.
6. LEVIS M, SMALL D: FLT3: ITDoes matter in leukemia. Leukemia (2003) 17:1738-1752.
7. BISHOP JF: The treatment of adult acute myeloid leukemia. Semin. Oncol. (1997) 24:57-69.
8. TSE KF, NOVELLI E, CIVIN CI, BOHMER FD, SMALL D: Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia (2001) 15:1001-1010.
9. LEVIS M, TSE KF, SMITH BD, GARRETT E, SMALL D: A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood (2001) 98:885-887.
10. LEVIS M, ALLEBACH J, TSE KF et al.: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 99:3885-3891.
11. KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1:421-432.
12. WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1:433-443.
13. TELLER S, KRAMER D, BOHMER SA et al.: Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia (2002) 16:1528-1534.
14. O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101:3597-3605.
15. YEE KW, O'FARRELL AM, SMOLICH BD et al.: SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood (2002) 100:2941-2949.
16. GAZIT A, YEE K, UECKER A et al.: Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg. Med. Chem. (2003) 11:2007-2018.
17. MURATA K, KUMAGAI H, KAWASHIMA T et al.: Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active FMS-like tyrosine kinase 3 (FLT3). J. Biol. Chem. (2003) 278(35):32892-32898
18. ROSNET O, SCHIFF C, PEBUSQUE MJ et al.: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 82:1110-1119.
19. SMALL D, LEVENSTEIN M, KIM E et al.: STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA (1994) 91:459-463.
20. VAN DER GEER P, HUNTER T, LINDBERG RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann. Rev Cell Biol. (1994) 10:251-337.
21. WYBENGA-GROOT LE, BASKIN B, ONG SH et al.: Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell (2001) 106:745-757.
22. HUSE M, MUIR TW, XU L et al.: The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell (2001) 8:671-682.
23. HUBBARD SR: Theme and variations: juxtamembrane regulation of receptor protein kinases. Mol. Cell (2001) 8:481-482.
24. DOSIL M, WANG S, LEMISCHKA IR: Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol. Cell. Biol. (1993) 13:6572-6585.
25. ROSNET O, BUHRING HJ, DELAPEYRIERE O et al.: Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. (1996) 95:218-223.
26. LAVAGNA-SEVENIER C, MARCHETTO S, BIRNBAUM D, ROSNET O: FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia (1998) 12:301-310.
27. LAVAGNA-SEVENIER C, MARCHETTO S, BIRNBAUM D, ROSNET O: The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J. Biol. Chem. (1998) 273:14962-14967.
28. ZHANG S, MANTEL C, BROXMEYER HE: Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. (1999) 65:372-380.
29. MARCHETTO S, FOURNIER E, BESLU N et al.: SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia (1999) 13:1374-1382.
30. ZHANG S, FUKUDA S, LEE Y et al.: Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. (2000) 192:719-728.
31. HANNUM C, CULPEPPER J, CAMPBELL D et al.: Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (1994) 368:643-648.
32. LYMAN SD, JAMES L, JOHNSON L et al.: Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood (1994) 83:2795-2801.
33. + progenitor cells isolated from human bone marrow are functionally distinct. Blood (1998) 91:1947-1958.
34. MACKAREHTSCHIAN K, HARDIN JD, MOORE KA et al.: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity (1995) 3:147-161.
35. MCKENNA HJ, STOCKING KL, MILLER RE et al.: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 95:3489-3497.
36. RAY RJ, PAIGE CJ, FURLONGER C, LYMAN SD, ROTTAPEL R: Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur. J. Immunol. (1996) 26:1504-1510.
37. VEIBY OP, JACOBSEN FW, CUI L, LYMAN SD, JACOBSEN SE: The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J. Immunol. (1996) 157:2953-2960.
38. BROXMEYER HE, LU L, COOPER S et al.: Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol. (1995) 23:1121-1129.
39. HIRAYAMA F, LYMAN SD, CLARK SC, OGAWA M: The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood (1995) 85:1762-1768.
40. NICHOLLS SE, WINTER S, MOTTRAM R, MIYAN JA, WHETTON AD: Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. Exp. Hematol. (1999) 27:663-672.
41. + hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood (2003) 102:881-886.
42. MEIERHOFF G, DEHMEL U, GRUSS HJ et al.: Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia (1995) 9:1368-1372.
43. DREXLER HG: Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia (1996) 10:588-599.
44. CAROW CE, LEVENSTEIN M, KAUFMANN SH et al.: Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood (1996) 87:1089-1096.
45. BIRG F, COURCOUL M, ROSNET O et al.: Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood (1992) 80:2584-2593.
46. ROSNET O, BUHRING HJ, MARCHETTO S et al.: Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 10:238-248.
47. NAKAO M, YOKOTA S, IWAI T et al.: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 10:1911-1918.
48. KIYOI H, TOWATARI M, YOKOTA S et al.: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 12:1333-1337.
49. KIYOI H, NAOE T, NAKANO Y et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 93:3074-3080.
50. ROMBOUTS WJ, BLOKLAND I, LOWENBERG B, PLOEMACHER RE: Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia (2000) 14:675-683.
51. ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. (2000) 111:190-195.
52. STIREWALT DL, KOPECKY KJ, MESHINCHI S et al.: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 97:3589-3595.
53. KOTTARIDIS PD, GALE RE, FREW ME et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood (2001) 98:1752-1759.
54. WHITMAN SP, ARCHER KJ, FENG L et al.: Absence of the wild-type allele predicts poor prognosis in adult de nove acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. (2001) 61:7233-7239.
55. IWAI T, YOKOTA S, NAKAO M et al.: Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia (1999) 13:38-43.
56. XU F, TAKI T, YANG HW et al.: Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. (1999) 105:155-162.
57. KONDO M, HORIBE K, TAKAHASHI Y et al.: Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol. (1999) 33:525-529.
58. MESHINCHI S, WOODS WG, STIREWALT DL et al.: Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 97:89-94.
59. THIEDE C, STEUDEL C, MOHR B et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood (2002) 99:4326-4335.
60. SCHNITTGER S, SCHOCH C, DUGAS M et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 100:59-66.
61. BOISSEL N, CAYUELA JM, PREUDHOMME C et al.: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia (2002) 16:1699-1704.
62. TILL JH, ABLOOGLU AJ, FRANKEL M et al.: Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism. J. Biol. Chem. (2001) 276:10049-10055.
63. FURITSU T, TSUJIMURA T, TONO T et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. (1993) 92:1736-1744.
64. JEFFERS M, SCHMIDT L, NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94:11445-11450.
65. SANTORO M, CARLOMAGNO F, ROMANO A et al.: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 267:381-383.
66. BEGHINI A, PETERLONGO P, RIPAMONTI CB et al.: c-kit mutations in core binding factor leukemias. Blood (2000) 95:726-727.
67. NAGATA H, WOROBEC AS, OH CK et al.: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA (1995) 92:10560-10564.
68. YAMAMOTO Y, KIYOI H, NAKANO Y et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 97:2434-2439.
69. ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. (2001) 113:983-988.
70. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
71. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
72. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347:472-480.
73. LANGE B, VALTIERI M, SANTOLI D et al.: Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 70:192-199.
74. MATSUO Y, MacLEOD RA, UPHOFF CC et al.: Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia (1997) 11:1469-1477.
75. MOSMANN T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods (1983) 65:55-63.
76. ORMEROD MG: The study of apoptotic cells by flow cytometry. Leukemia (1998) 12:1013-1025.
77. TSE KF, ALLEBACH J, LEVIS M et al.: Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia (2002) 16:2027-2036.
78. ARMSTRONG SA, KUNG AL, MABON ME et al.: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3:173-183.
79. LAMERS MB, ANTSON AA, HUBBARD RE, SCOTT RK, WILLIAMS DH: Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. (1999) 285:713-725.
80. BOHMER FD, KARAGYOZOV L, UECKER A et al.: A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. (2003) 278:5148-5155.
81. NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236-4243.
82. GRUNDLER R, THIEDE C, MIETHING C et al.: Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood (2003) 102:646-651.
83. KOVALENKO M, GAZIT A, BOHMER A et al.: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. (1994) 54:6106-6114.
84. GAZIT A, APP H, MCMAHON G et al.: Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J. Med. Chem. (1996) 39:2170-2177.
85. UEDA S, IKEDA H, MIZUKI M et al.: Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int. J. Hematol. (2002) 76:427-435.
86. GRIFFIN JH, LEUNG J, BRUNER RJ, CALIGIURI MA, BRIESEWITZ R: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA (2003) 100:7830-7835.
87. WHITMAN SP, GUIMOND M, BLASER B et al.: Primary acute myeloid leukemia (AML) cells with the FLT3 internal tandem duplication (ITD) and absence of wild type (WT) FLT3 (FLT3ITD/- genotype) are distinct from AML with either FLT3wt/wtor FLT3ITD/wt genotypes. Blood (2002) 100:89a (Abstract).
88. FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99-106.
89. MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Des. (2000) 15:29-41.
90. SMOLICH BD, YUEN HA, WEST KA et al.: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood (2001) 97:1413-1421.
91. GILES FJ, COOPER MA, SILVERMAN L et al.: Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer (2003) 97:1920-1928.
92. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
93. ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471-478.
94. RUEGG UT, BURGESS GM: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. (1989) 10:218-220.
95. YAMADA K, IWAHASHI K, KASE H: K252a, a new inhibitor of protein kinase C, concomitantly inhibits 40K protein phosphorylation and serotonin secretion in a phorbol ester-stimulated platelets. Biochem. Biophys. Res. Commun. (1987) 144:35-40.
96. NAKANISHI S, MATSUDA Y, IWAHASHI K, KASE H: K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J. Antibiot. (Tokyo) (1986) 39:1066-1071.
97. NAKANO H, KOBAYASHI E, TAKAHASHI I et al.: Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J. Antibiot. (Tokyo) (1987) 40:706-708.
98. GEORGE DJ, DIONNE CA, JANI J et al.: Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59:2395-2401.
99. FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. (1999) 82:293-301.
100. KELLY LM, LIU Q, KUTOK JL et al.: FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood (2002) 99:310-318.
101. PANDEY A, VOLKOTS DL, SEROOGY JM et al.: Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. (2002) 45:3772-3793.
102. YU JC, LOKKER NA, HOLLENBACH S et al.: Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J. Pharmacol. Exp. Ther. (2001) 298:1172-1178.
103. FIEDLER W, MESTERS R, TINNEFELD H et al.: A Phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003)
104. SMITH BD, LEVIS M, BROWN P et al.: Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood (2002) 100:85a (Abstract).
105. STONE R, KLIMECK V, DEANGELO DJ et al.: PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a Phase II clinical trial. Blood (2002) 100:86a (Abstract).
106. HEINRICH MC, DRUKER B, CURTIN P et al.: A 'first in man' study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Blood (2002) 100:336a (Abstract).
107. FORAN J, PAQUETTE R, COOPER MA et al.: A Phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy. Blood (2002) 100:558a (Abstract).